| Autor: |
Bouchal Pavel, Jarkovsky Jiri, Hrazdilova Kristyna, Dvorakova Monika, Struharova Iva, Hernychova Lenka, Damborsky Jiri, Sova Petr, Vojtesek Borivoj |
| Jazyk: |
angličtina |
| Rok vydání: |
2011 |
| Předmět: |
|
| Zdroj: |
Proteome Science, Vol 9, Iss 1, p 68 (2011) |
| Druh dokumentu: |
article |
| ISSN: |
1477-5956 |
| DOI: |
10.1186/1477-5956-9-68 |
| Popis: |
Abstract Background The initial pharmacokinetic study of a new anticancer agent (OC-6-43)-bis(acetato)(1-adamantylamine)amminedichloroplatinum (IV) (LA-12) was complemented by proteomic screening of rat plasma. The objective of the study was to identify new LA-12 target proteins that serve as markers of LA-12 treatment, response and therapy monitoring. Methods Proteomic profiles were measured by surface-enhanced laser desorption-ionization time-of-flight mass spectrometry (SELDI-TOF MS) in 72 samples of rat plasma randomized according to LA-12 dose and time from administration. Correlation of 92 peak clusters with platinum concentration was evaluated using Spearman correlation analysis. Results We identified Retinol-binding protein 4 (RBP4) whose level correlated with LA-12 level in treated rats. Similar results were observed in randomly selected patients involved in Phase I clinical trials. Conclusions RBP4 induction is in agreement with known RBP4 regulation by amantadine and cisplatin. Since retinol metabolism is disrupted in many cancers and inversely associates with malignancy, these data identify a potential novel mechanism for the action of LA-12 and other similar anti-cancer drugs. |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
